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CASE REPORT
A 62-year-old never smoker white woman was diag-
nosed with stage IV lung adenocarcinoma. Staging revealed 
a left lower lobe primary, an associated pleural effusion and 
multiple bony and hepatic metastases (Fig. 1). An interven-
tional radiology-guided core biopsy of the primary lesion 
was performed, which demonstrated a well-differentiated 
adenocarcinoma that was TTF-1 and CK7 positive and CK20 
negative by immunohistochemistry. Epidermal growth factor 
receptor (EGFR) mutation analysis was performed via the 
EGFR Rotor-Gene Q Instrument (RGQ) polymerase chain 
reaction assay (Qiagen, Manchester, United Kingdom) show-
ing a G719X mutation (exon 18). The patient was started 
on erlotinib at 150 mg daily. Restaging positron emission 
tomography/computed tomography revealed decreased size 
and metabolic activity of the primary lesion and resolution 
of a hepatic metastasis (Fig. 2). Approximately 9 months 
after starting erlotinib, restaging positron emission tomog-
raphy/computed tomography revealed disease progression 
with new left pleural thickening and worsening effusion. A 
left-sided video-assisted thoracoscopic surgery with biopsy 
and pleurodesis was performed for symptom management 
and further molecular diagnostics. Mutational analysis per-
formed at the Colorado Molecular Correlates Laboratory 
at the University of Colorado Hospital using the ABIPrism 
SNaPshot multiplex polymerase chain reaction platform 
(Applied Biosystems, Forest City, CA) followed by direct 
sequencing duplicated her previously known G719X muta-
tion, which was further clarified to be a c.2156G > A 
(p.G719D) mutation in addition to a c.2582T > G (p.L861R) 
point mutation in exon 21. Repeat molecular testing of 
the patient’s original diagnostic biopsy was performed at 
Colorado Molecular Correlates Laboratory, with both muta-
tions (G719D and L861R) identified. The patient continued 
on erlotinib postprocedure in anticipation of enrollment in a 
clinical trial when she presented with progressive confusion, 
memory loss, and disease progression in the central nervous 
system, as determined by magnetic resonance imaging. The 
patient elected to forgo further therapy and enrolled in hos-
pice, passing 11 months after initial diagnosis.
COMMENT
Missense mutations at position 719 in exon 18 of EGFR 
gene (G719A/S/V/D) have been previously described, occur-
ring in approximately 3% of all known EGFR mutations and 
cause constitutive activation of EGFR.1–3 Mutations at position 
861 (most commonly L861Q) have been described, occur-
ring in approximately 2% of all EGFR-mutant patients.1 The 
specific mutations identified in this case are the least com-
mon of mutations at these two loci, and compound mutations 
with G719D and L861R have not been previously described. 
A recent retrospective analysis described objective response 
rates (ORR) of 53.3% on EGFR tyrosine kinase inhibi-
tors with a median progression-free survival (PFS) of 8.1 
months, and a median overall survival (OS) of 16.4 months 
in a G719X patient cohort. A patient cohort with L861Q 
EGFR mutated NSCLC demonstrated an ORR of 60%, PFS 
and OS of 6.0 and 15.2 months, respectively. Both cohorts 
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FIGURE 1.  Combined positron emission tomography/com-
puted tomography images with thoracic imaging (A and B) 
demonstrating disease burden at initial staging (A) and initial 
response (B). Axial images of hepatic metastases (C and D) 
from initial staging (C) and initial response (D).
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performed comparatively worse than the cohort harboring the 
more common deletion exon 19 and L858R mutations (ORR 
74.1%; PFS 8.5 months; OS 19.6 months).4 Direct sequenc-
ing of exon 18 to 21 in 79 known EGFR-mutation–positive 
patients demonstrated a compound mutation rate of 14% with 
three response-evaluable patients harboring a G719X com-
pound mutation and modest response to erlotinib with no par-
tial response greater than 8 months and no OS greater than 
12 months.5 These outcomes are consistent with our patient’s 
excellent but short-lived response.
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FIGURE 2.  Chromatograms demonstrating epidermal 
growth factor receptor mutations G719D exon 18 (A) and 
L861R in exon 21 (B) as detected in the October 2012 rebi-
opsy sample. Both mutations were identified in the pretreat-
ment sample upon repeat analysis.
